EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cangemi, V.
Right arrow Articles by Piat, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cangemi, V.
Right arrow Articles by Piat, G.

European Journal of Cardio-Thoracic Surgery, Vol 9, 352-359, Copyright © 1995 by European Association for Cardio-thoracic Surgery


ARTICLES

Results of surgical treatment of stage IIIA non-small cell lung cancer

V Cangemi, P Volpino, N D'Andrea, F Chiarotti, R Tomassini and G Piat
Ist Department of Surgery, University of Rome, La Sapienza, Italy.

From 1975 to 1993, 665 patients with non-small cell lung carcinoma (NSCLC) were studied in our Unit. Of the 55 stage IIIA patients submitted to resection, 50 were followed-up in order to evaluate the effectiveness of surgery and to identify which variables had a prognostic impact on survival. The expectancy of survival at 3,5 and 10 years was 31.7, 19.5 and 13.7%, respectively. When the analysis was limited to N2 patients, 3,5- and 10-year survival rates were 20.9, 14 and 7%, respectively. Regarding the "TN" factor, the T3N0 subset presented the highest expected survival (24.8 and 18.6% at 5 and 10 years). With regard to the "T3" factor and type of surgery, peripheral tumors submitted to en bloc resection of the chest wall showed the best 5-year survival rate (42.9%), whereas extrapleural resections--even for tumors confined to the parietal pleura--showed a 5-year survival rate of 14.3%. A slightly higher risk of death was observed in tumors originating in the superior sulcus (SST). No patients with mediastinal pleura and pericardium involvement survived more than 34 months. With univariate analysis, "N2" was the variable most significantly associated with a negative prognosis when related to T3 (T3N2 vs T3N0 0.025 < P < 0.05) or non-epidermoid tumor (no survivors at 3 years; N2 epidermoid vs N2 non-epidermoid tumor P < 0.05). Applying multivariate analysis, epidermoid cell type, even if exclusively for N2 tumors, was an independent prognostic factor, showing a favorable impact on survival expectancy (27.8% at 90 months).


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
M. Riquet, L. Lang-Lazdunski, F. Le Pimpec-Barthes, A. Dujon, R. Souilamas, C. Danel, and D. Manac'h
Characteristics and prognosis of resected T3 non-small cell lung cancer
Ann. Thorac. Surg., January 1, 2002; 73(1): 253 - 258.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. Inoue, M. Sato, S. Fujimura, A. Sakurada, S. Takahashi, K. Usuda, T. Kondo, T. Tanita, M. Handa, Y. Saito, et al.
Prognostic assessment of 1310 patients with non-small-cell lungcancer who underwent complete resection from 1980 to 1993
J. Thorac. Cardiovasc. Surg., September 1, 1998; 116(3): 407 - 411.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.